These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29542858)

  • 1. Effect of additional antihypertensive medications in patients with high-risk hypertension: a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) database.
    Nguyen LS
    J Clin Hypertens (Greenwich); 2018 Apr; 20(4):814-815. PubMed ID: 29542858
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
    J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.
    Aggarwal R; Mirzan H; Chiu N; Steinkamp J
    Clin Res Cardiol; 2018 Jul; 107(7):565-569. PubMed ID: 29480390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.
    Lee TC; Cavalcanti RB; McDonald EG; Pilote L; Brophy JM
    Am J Med; 2018 Oct; 131(10):1228-1233.e1. PubMed ID: 29906425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the SPRINT Trial on Hypertension Management.
    Ghazi L; Oparil S
    Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis.
    Verdecchia P; Angeli F; Gentile G; Reboldi G
    Hypertension; 2016 Sep; 68(3):642-53. PubMed ID: 27456518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Blood Pressure Treatment Reduced Stroke Risk in Patients With Albuminuria in the SPRINT Trial.
    Leitão L; Soares-Dos-Reis R; Neves JS; Baptista RB; Bigotte Vieira M; Mc Causland FR
    Stroke; 2019 Dec; 50(12):3639-3642. PubMed ID: 31637971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can low blood pressure also have risks? (interview by Dr. med. Jochen Aumiller)].
    Kolloch R
    MMW Fortschr Med; 2004 Apr; 146(16):18. PubMed ID: 15222495
    [No Abstract]   [Full Text] [Related]  

  • 12. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPRINT in context: meta-analysis of trials with baseline normotension and low levels of previous cardiovascular disease.
    Brunström M; Carlberg B
    J Hypertens; 2018 May; 36(5):979-986. PubMed ID: 29300245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPRINT trial: It's not just the blood pressure!
    Berkelmans GF; Visseren FL; Jaspers NE; Spiering W; van der Graaf Y; Dorresteijn JA
    Eur J Prev Cardiol; 2017 Sep; 24(14):1482-1484. PubMed ID: 28749177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Wang KM; Stedman MR; Chertow GM; Chang TI
    Hypertension; 2020 Dec; 76(6):1725-1733. PubMed ID: 33131314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials.
    Bangalore S; Toklu B; Gianos E; Schwartzbard A; Weintraub H; Ogedegbe G; Messerli FH
    Am J Med; 2017 Jun; 130(6):707-719.e8. PubMed ID: 28109971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental effects of antihypertensive drugs: instrumental variable analysis.
    Markovitz AA; Mack JA; Nallamothu BK; Ayanian JZ; Ryan AM
    BMJ; 2017 Dec; 359():j5542. PubMed ID: 29273586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.